Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan Wade Goldman, Mikhail Vladimirovich Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020

Cited by 688 works. doi:10.1016/s1470-2045(20)30539-8

Authors

References